Cardobis® 1.25 FCT: Each film-coated Tablet contains Bisoprolol Fumarate USP 1.25 mg.
Cardobis 2.5 FCT: Each film-coated Tablet contains Bisoprolol Fumarate USP 2.5 mg.
Cardobis® 5 FCT: Each film-coated Tablet contains Bisoprolol Fumarate USP 5 mg.
Cardobis® is a preparation of Bisoprolol Fumarate. Bisoprolol Fumarate is a beta1-selective (cardioselective) adrenoceptor blocking agent without significant membrane stabilizing activity or intrinsic sympathomimetic activity in its therapeutic dosage range. Cardioselectivity is not absolute, however, and at higher doses (>20 mg) Bisoprolol Fumarate also inhibits beta 2-adrenoceptors, chiefly located in the bronchial and vascular musculature; to retain selectivity it is therefore important to use the lowest effective dose.
Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when Bisoprolol Fumarate is administered to a nursing woman.
Patients, especially those with coronary artery disease, should be warned about discontinuing use of Bisoprolol Fumarate without a physician's supervision. Patients should also be advised to consult a physician if any difficulty in breathing occurs, or if they develop signs or symptoms of congestive heart failure or excessive bradycardia. Patients subject to spontaneous hypoglycemia or diabetic patients receiving insulin or oral hypoglycemic agents should be cautioned that beta-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia and Bisoprolol Fumarate should be used with caution. Patients should know how they react to this medicine before they operate automobiles and machinery or engage in other tasks requiring alertness.
Do not store above 30°C temperature. Keep away from light and wet place. Keep out of reach of children.